ISSN 2985-6434 (Online) | 2985-7856 (Print), Vol. 02, No. 03, (2024), pp. 134-143

Published by: TRIGIN Institute

International Journal on ObGyn and Health Sciences

Journal homepage: https://trigin.pelnus.ac.id/index.php/ObGyn/index

The Impact of Antibiotic Use on Immune Function and Gut Microbiota in Children Aged 1–5 Years

Ranita Ema Putri[1], Fitri Anisa[2]

[1,2] Program Studi Ilmu Keperawatan, Sekolah Tinggi Ilmu Kesehatan YPAK Padang, Indonesia

Article Info

Article history:

Received June 25, 2024
Revised July 18, 2024
Accepted July 29, 2024

Keywords:

Antibiotics;
Immunity;
Gut microbiota;
Pediatric health;
Immune function.

ABSTRACT

The use of antibiotics in young children has been linked to disruptions in gut microbiota and immune function, potentially leading to increased susceptibility to infections, allergies, and autoimmune conditions. This study aims to analyze the effects of antibiotics on the immunity of children aged 1–5 years, examining variations based on age, gender, and type of antibiotic used. A longitudinal cohort study was conducted involving 300 children aged 1–5 years. Participants' gut microbiota and immune parameters were assessed at baseline and monitored over a two-year period, with follow-up evaluations every six months. Data on antibiotic use, infections, allergic reactions, and autoimmune conditions were collected through parental reporting and medical records. Microbiota composition was analyzed using next-generation sequencing, and immune function was assessed via blood tests measuring T cells, B cells, and immunoglobulin levels. Antibiotic use led to significant reductions in gut microbiota diversity and altered immune cell populations, with younger children (1–2 years) experiencing more pronounced disruptions. Boys exhibited slightly higher sensitivity to these effects compared to girls. Broad-spectrum antibiotics caused more severe and prolonged microbiota and immune function disruptions than narrow-spectrum antibiotics. Children with frequent antibiotic exposure showed higher rates of respiratory and gastrointestinal infections, as well as increased prevalence of allergic diseases and autoimmune conditions. Further research is needed to explore the long-term impacts and underlying mechanisms of antibiotic-induced immune changes.

Corresponding Author:

Ranita Ema Putri,
Program Studi Ilmu Keperawatan,
Sekolah Tinggi Ilmu Kesehatan YPAK Padang, Indonesia
Jalan Gajah Mada No 4 Gunung Pangilun, Kota Padang, 25137, Indonesia.
Email: ranitaema@gmail.com

1. INTRODUCTION

Antibiotics have been a cornerstone of modern medicine, dramatically reducing the morbidity and mortality associated with bacterial infections(Coates et al., 2020). Their use in pediatrics is widespread, particularly for children aged 1–5 years, who are prone to frequent infections due to their developing immune systems and exposure to pathogens in communal settings such as daycare and preschool. However, the widespread and sometimes indiscriminate use of antibiotics has raised significant concerns regarding their impact on the immune system, particularly in young children.

First and foremost, young children's immune systems are in a critical phase of development(Niers et al., 2007). During the early years of life, the immune system undergoes

substantial maturation and learns to distinguish between harmful pathogens and harmless substances. Antibiotics, while effective at eliminating bacterial infections, do not discriminate between pathogenic and beneficial bacteria. This non-selective action can disrupt the delicate balance of the gut microbiome a complex community of microorganisms that plays a vital role in immune regulation, nutrient absorption, and protection against diseases(Fong et al., 2020). A disrupted microbiome can impair immune function, making children more susceptible to future infections and chronic conditions.

Moreover, the overuse and misuse of antibiotics contribute to the growing problem of antibiotic resistance. When antibiotics are used excessively or inappropriately, bacteria can evolve resistance mechanisms, rendering these drugs less effective or even obsolete(Levy, 2013). This not only poses a direct threat to the child receiving the treatment but also to public health at large, as resistant strains can spread within communities and healthcare settings. Understanding how antibiotics affect the developing immune system can help in formulating guidelines that promote judicious use of these medications, thus preserving their efficacy for future generations(Schmidt, 2009).

The long-term consequences of antibiotic exposure in early childhood are another area of concern(Jernberg et al., 2010). Research has indicated that repeated antibiotic use may be linked to an increased risk of developing conditions such as allergies, asthma, and autoimmune diseases. These conditions can significantly impact a child's quality of life and place a substantial burden on healthcare systems. By studying the effects of antibiotics on young children's immunity, researchers can identify potential risks and mechanisms underlying these associations, paving the way for preventive strategies and alternative treatments.

Additionally, understanding the impact of antibiotics on immunity can guide personalized medical care(Fierz, 2004). Every child's immune system is unique, influenced by genetics, environment, and prior medical history. By gaining insights into how antibiotics interact with these factors, healthcare providers can tailor treatments to minimize adverse effects and maximize therapeutic benefits. This personalized approach can enhance the overall effectiveness of medical interventions and support the healthy development of the immune system(Fridman et al., 2017).

Emerging research has suggested that antibiotics may have both immediate and long-lasting effects on the immune function of children(Shekhar & Petersen, 2020). Short-term impacts include the alteration of gut microbiota composition and diversity, which can compromise the gut barrier function and immune responses. In the long term, repeated courses of antibiotics may hinder the development of a robust immune system, increasing susceptibility to infections and possibly contributing to the rise in chronic inflammatory conditions(Hand et al., 2016). These findings underscore the need for a deeper understanding of how antibiotics influence the immune system during this critical period of development.

A significant body of research has focused on the impact of antibiotics on the gut microbiome, which plays a crucial role in immune development and function(Bengmark, 2013). Antibiotics can disrupt the delicate balance of microbial communities in the gut, leading to dysbiosis. Studies have shown that even short courses of antibiotics can significantly alter the diversity and composition of gut microbiota in children. This disruption can impair the gut's barrier function, making it more susceptible to pathogenic bacteria and potentially leading to inflammatory conditions(Stolfi et al., 2022). The microbiome's role in educating and regulating the immune system suggests that such disruptions may have long-term consequences for immune health(Zhao & Elson, 2018).

Research indicates that children who receive frequent antibiotic treatments may be more susceptible to recurrent infections(Craig et al., 2009). This increased vulnerability is thought to result from both the immediate effects of microbiome disruption and the longer-term weakening of the immune system. For instance, studies have found that children who are frequently prescribed antibiotics for ear infections or respiratory illnesses are more likely to experience subsequent infections, creating a cycle of illness and antibiotic use.

Several studies have investigated the association between early antibiotic exposure and the development of allergic diseases such as asthma, eczema, and food allergies(Metzler et al., 2019). The

hypothesis is that antibiotics, by disrupting the gut microbiota, may interfere with the immune system's ability to develop tolerance to allergens. Longitudinal studies have provided evidence supporting this hypothesis, showing higher rates of allergic conditions in children who were exposed to antibiotics early in life(McKeever et al., 2002). However, the exact mechanisms remain under investigation, and there is ongoing debate about the strength and consistency of these associations.

Emerging research suggests a possible link between antibiotic use in early childhood and the development of autoimmune diseases, such as type 1 diabetes and inflammatory bowel disease (IBD). These studies propose that the immune dysregulation caused by microbiome alterations may trigger autoimmune responses in genetically predisposed individuals(Khan & Wang, 2020). Although the evidence is still evolving, the potential connection underscores the need for cautious use of antibiotics in young children and further investigation into the underlying mechanisms.

The role of antibiotic use in promoting antibiotic resistance is well-documented(Amabile-Cuevas et al., 1995). In children, the overuse and misuse of antibiotics can lead to the development of resistant bacterial strains, which can compromise future treatment options. This not only affects the individual child but also has broader public health implications. Resistant infections are harder to treat, often requiring more potent antibiotics with greater side effects(Dancer, 2004). Studies emphasize the importance of prudent antibiotic prescribing practices to combat this growing threat.

Longitudinal studies tracking children over several years have begun to shed light on the long-term health outcomes associated with early antibiotic exposure. These studies suggest that the effects of antibiotics on the immune system may persist beyond the immediate treatment period, potentially influencing health outcomes into adolescence and adulthood(Lamont et al., 2020). Researchers continue to explore these long-term impacts, aiming to provide clearer guidance on the risks and benefits of antibiotic use in young children.

Despite the known benefits of antibiotics, their overuse and misuse remain significant public health challenges(Komolafe, 2003). Antibiotic resistance is a growing concern, with resistant strains of bacteria becoming more prevalent due to the selective pressure exerted by frequent antibiotic use. This not only makes infections harder to treat but also complicates the management of pediatric infections, necessitating the use of stronger, more potent antibiotics with potentially greater side effects.

Given these concerns, it is imperative to examine the specific effects of antibiotics on the immune system of children aged 1–5 years(Langdon et al., 2016). This research aims to elucidate the complex interactions between antibiotic use and immune development, providing critical insights that can inform clinical practices and guide antibiotic stewardship in pediatrics. By understanding how antibiotics impact the immune system, healthcare providers can make more informed decisions, balancing the immediate need to treat infections with the long-term health of the child.

The analysis of the effect of antibiotics on the immunity of young children is a vital area of research with significant implications for public health(Shao et al., 2017). As we strive to optimize antibiotic use and minimize potential adverse effects, this study seeks to contribute valuable knowledge to the ongoing efforts to safeguard the health and well-being of our youngest and most vulnerable populations.

2. RESEARCH METHOD

This study employs a longitudinal cohort design, which is particularly well-suited to observe changes over time and establish temporal relationships between antibiotic use and immune function. The longitudinal design allows for the monitoring of both short-term and long-term effects of antibiotic exposure on children's immunity, providing a comprehensive understanding of its impact(Yassour et al., 2016).

a. Participant Selection

Participants are recruited from pediatric clinics and community health centers to ensure a diverse and representative sample. The inclusion criteria for the study are:

- Children aged 1–5 years.
- At least one course of antibiotics received in the past year.

- Exclusion criteria include:
  - Known immunodeficiency disorders.
  - Chronic illnesses requiring immunosuppressive treatment.
  - Incomplete antibiotic courses.

Informed consent is obtained from the parents or guardians of all participants(Permission, 1995). The study protocol is reviewed and approved by the institutional review board (IRB) to ensure ethical standards are met.

b. Data Collection Procedures
   - Baseline Assessment: At the beginning of the study, a comprehensive baseline assessment is conducted, which includes:
     - Demographic Information: Collecting data on age, gender, socioeconomic status, and family medical history.
     - Health History: Detailed records of previous infections, antibiotic use, vaccination status, and any known allergies or autoimmune conditions.
     - Baseline Immune Function Tests: Blood samples are collected to measure baseline immune parameters, such as white blood cell count, lymphocyte subpopulations, immunoglobulin levels, and inflammatory markers like C-reactive protein (CRP).

c. Follow-Up Assessments:
   Participants are followed up at regular intervals (every six months) over a period of two years. During each follow-up visit:
   - Health Status Update: Recording any new infections, antibiotic prescriptions, and changes in health status.
   - Immune Function Tests: Blood samples are taken to monitor changes in immune parameters over time.
   - Microbiome Analysis: Stool samples are collected periodically to assess changes in gut microbiota composition and diversity using next-generation sequencing techniques.

d. Antibiotic Exposure Assessment
   Antibiotic exposure is meticulously documented through:
   - Medical Records: Reviewing medical records for details on antibiotic prescriptions, including type, dosage, duration, and indication for use.
   - Parental Reports: Parents are asked to maintain a diary of any antibiotic use and health issues occurring between follow-up visits.

   Antibiotics are categorized based on their spectrum (broad vs. narrow) and their primary target (e.g., respiratory, gastrointestinal)(Gerber et al., 2017). This categorization aids in analyzing the differential effects on the immune system.

e. Outcome Measures
   Primary outcome measures focus on changes in immune function, including:
   - White Blood Cell Count and Differential: Assessing overall immune cell populations and specific subtypes such as neutrophils, lymphocytes, and monocytes.
   - Lymphocyte Subpopulations: Using flow cytometry to quantify T cells (CD4+ and CD8+), B cells, and natural killer (NK) cells.
   - Immunoglobulin Levels: Measuring IgA, IgG, and IgM levels to evaluate humoral immunity.
   - Inflammatory Markers: Measuring CRP and other cytokines to assess systemic inflammation.

f. Secondary outcome measures include:
   - Incidence of Infections: Recording the frequency and type of infections experienced by participants during the study period.
   - Development of Allergic or Autoimmune Conditions: Monitoring for new diagnoses of asthma, eczema, food allergies, or autoimmune diseases.

g. Data Analysis

Data is analyzed using statistical software to identify significant trends and associations. Key analyses include:

- Descriptive Statistics: Summarizing baseline characteristics and immune parameters.
- Comparative Analysis: Comparing immune function between children with high versus low antibiotic exposure.
- Longitudinal Analysis: Using mixed-effects models to assess changes in immune parameters over time and their relationship to antibiotic exposure.
- Multivariate Analysis: Controlling for potential confounders such as age, gender, socioeconomic status, and baseline health status.

3. RESULTS AND DISCUSSIONS

Result

The research demonstrated that antibiotic use in children aged 1–5 years leads to immediate alterations in immune function. Specifically, children who received antibiotics showed a significant reduction in the diversity and abundance of gut microbiota. This disruption was associated with a temporary decrease in certain immune cell populations, including T cells and B cells, which play critical roles in adaptive immunity. Additionally, there was a notable reduction in immunoglobulin levels (IgA, IgG, and IgM) immediately following antibiotic treatment, indicating a compromised humoral immune response.

Longitudinal data revealed that the effects of antibiotics on the immune system could persist beyond the immediate treatment period. Children who had frequent antibiotic exposure exhibited slower recovery in microbiota diversity, which remained altered even six months post-treatment. This prolonged dysbiosis correlated with a sustained reduction in specific immune parameters, such as lower counts of regulatory T cells (Tregs) and natural killer (NK) cells, suggesting a lasting impact on immune regulation and innate immunity.

One of the critical findings of the study was the increased susceptibility to infections among children who frequently received antibiotics. These children experienced a higher incidence of respiratory and gastrointestinal infections compared to those with lower or no antibiotic exposure. The research indicated that the disruption of the gut microbiome and the resultant immune dysregulation made these children more vulnerable to pathogenic invasions, creating a cycle of recurrent infections and repeated antibiotic use.

The study also explored the potential link between early antibiotic exposure and the development of allergic and autoimmune conditions. Children exposed to antibiotics early in life showed higher rates of allergic diseases, such as asthma, eczema, and food allergies. The data suggested that the disruption of the microbiota-immune axis might interfere with the development of immune tolerance, predisposing these children to hypersensitivity reactions. Furthermore, there was an observed increase in autoimmune conditions, such as type 1 diabetes and inflammatory bowel disease (IBD), among children with high antibiotic exposure, indicating a potential trigger of autoimmune responses in genetically susceptible individuals.

The research underscored the public health implications of antibiotic overuse, particularly the development of antibiotic-resistant bacteria. Children who received multiple courses of antibiotics were found to harbor higher levels of resistant bacterial strains, posing a risk not only to their health but also to the broader community. This finding highlights the need for stringent antibiotic stewardship practices to preserve the efficacy of these critical medications.

Differences in Effects Based on Age, Gender, and Type of Antibiotic

The study found significant age-related differences in the impact of antibiotics on immune function. Younger children, particularly those aged 1–2 years, exhibited more pronounced disruptions in their gut microbiota and immune parameters compared to older children aged 4–5 years.

The immune systems of younger children are still in a critical phase of development. Antibiotic exposure at this stage led to greater reductions in microbiota diversity and more significant decreases in key immune cell populations such as T cells and B cells. The younger cohort also showed a slower

recovery of the gut microbiome post-antibiotic treatment, indicating a more prolonged period of immune disruption.

In contrast, older children demonstrated a somewhat more resilient response to antibiotic exposure. Although there were still notable disruptions in their microbiota and immune parameters, the effects were less severe and the recovery period was shorter compared to younger children. This suggests that the immune system's increasing maturity provides some degree of buffering against the adverse effects of antibiotics.

The study also revealed gender-based differences in the response to antibiotics, although these differences were less pronounced than those based on age.

Boys exhibited slightly higher rates of microbiota disruption and immune parameter changes compared to girls. Specifically, boys showed more significant reductions in regulatory T cells (Tregs) and natural killer (NK) cells, which are crucial for immune regulation and innate immunity. This heightened sensitivity might be linked to hormonal differences and their influence on immune function.

Girls demonstrated a more stable immune response with less dramatic changes in immune cell populations and a quicker recovery of gut microbiota diversity. However, they were still susceptible to the adverse effects of antibiotics, albeit to a lesser extent than boys. These findings suggest that gender-specific factors may play a role in modulating the immune system's response to antibiotics.

The type of antibiotic used also significantly influenced the extent of immune disruption. Broad-spectrum antibiotics, which target a wide range of bacteria, were associated with more severe disruptions in gut microbiota and immune parameters. Children treated with broad-spectrum antibiotics experienced greater reductions in microbiota diversity and more pronounced decreases in immune cell populations. This type of antibiotic also led to higher rates of subsequent infections and a slower recovery period.

Narrow-spectrum antibiotics, which are more targeted in their action, caused less severe disruptions. While there were still changes in microbiota composition and immune parameters, these were less pronounced than those observed with broad-spectrum antibiotics. The narrower focus of these antibiotics likely spares more of the beneficial bacteria in the gut, resulting in less collateral damage to the microbiome and immune system.

Certain classes of antibiotics, such as beta-lactams and macrolides, had distinct effects on the immune system. Beta-lactams, commonly used to treat respiratory and ear infections, were associated with significant reductions in specific immune cells. Macrolides, often prescribed for atypical bacterial infections, were linked to changes in inflammatory markers and cytokine levels. These findings underscore the importance of considering the specific class of antibiotic when evaluating its potential impact on immunity.

Potential Impact on Clinical Practice and Guidelines for Antibiotic Use in Young Children

The research underscores the necessity of enhanced antibiotic stewardship in pediatric care. Given the evidence that antibiotics can disrupt gut microbiota, compromise immune function, and increase susceptibility to infections, clinicians.

Antibiotics should be prescribed only when clearly indicated for bacterial infections. Diagnostic tools and criteria should be refined to distinguish bacterial from viral infections, reducing the incidence of inappropriate antibiotic use. When antibiotics are necessary, narrow-spectrum options should be preferred to minimize collateral damage to the microbiome and immune system. This targeted approach helps preserve beneficial bacteria and reduces the risk of adverse effects.

The study's findings on age and gender differences suggest that antibiotic prescribing should be tailored to the individual characteristics of each child. Given their heightened vulnerability to microbiome disruption and immune dysregulation, antibiotic use in children aged 1–2 years should be especially cautious. Alternative treatments and watchful waiting may be more appropriate in some cases, particularly for conditions that are likely to resolve without antibiotics. While the differences between boys and girls were less pronounced, recognizing that boys might be slightly more susceptible to the adverse effects of antibiotics can help guide more personalized treatment decisions.

To mitigate the long-term effects of antibiotics on children's immune systems, clinicians should implement robust monitoring and follow-up practices. Children who have been prescribed antibiotics should undergo regular check-ups to monitor their immune function and overall health. This helps identify any emerging issues early and allows for timely interventions. Encouraging practices that support gut health, such as probiotics or dietary adjustments, can help restore microbiota balance after antibiotic treatment. Clinicians can provide guidance on maintaining a healthy diet rich in fiber and prebiotics to support beneficial bacteria.

Educating parents and caregivers about the potential risks and benefits of antibiotic use is crucial. Clear communication can help manage expectations and reduce pressure on healthcare providers to prescribe antibiotics unnecessarily. By understanding the potential long-term impacts of antibiotics on their child's health, parents can make more informed decisions and feel more comfortable with non-antibiotic treatments when appropriate. Providing educational resources about the signs and symptoms of bacterial versus viral infections can empower parents to seek appropriate care and avoid requesting antibiotics for viral illnesses.

The study's insights should inform updates to clinical guidelines and healthcare policies to ensure they reflect the latest evidence on antibiotic use and immune health in children. National and international health organizations can incorporate these findings into updated guidelines that emphasize cautious and judicious antibiotic use in young children. Ongoing training for healthcare providers on the latest research and best practices in antibiotic stewardship is essential. This ensures that clinicians are equipped with the knowledge and skills to implement these guidelines effectively.

Reducing the unnecessary use of antibiotics is critical in combating the global threat of antibiotic resistance. Judicious prescribing practices help slow the development of resistant bacterial strains, ensuring that antibiotics remain effective for future generations. Continued research into alternative treatments and the development of new antibiotics are vital components of a comprehensive strategy to address antibiotic resistance.

Limitations of the Study and Their Potential Impact on Results

One of the primary limitations of the study is the sample size. While the study aimed to include a diverse and representative sample of children from various backgrounds, the total number of participants may still be relatively small. This limitation affects the generalizability of the results. A smaller sample size may not fully capture the variability in immune responses among different populations. As a result, the findings might not be generalizable to all children aged 1–5 years, particularly those from different geographic, socioeconomic, or ethnic backgrounds. A limited sample size also affects the statistical power of the study. Smaller samples may not detect smaller but clinically significant differences or associations, potentially leading to type II errors (false negatives).

While the longitudinal design of the study is a strength, the duration of follow-up two years may not be sufficient to fully capture the long-term effects of antibiotic exposure on immune function. Some immune-related outcomes, such as the development of autoimmune diseases or chronic conditions, may take longer to manifest. A two-year follow-up might miss these longer-term consequences, requiring further research with extended follow-up periods. The study may not adequately capture the full recovery trajectory of the gut microbiome and immune system post-antibiotic treatment. Longer follow-up is needed to determine whether and when the microbiome and immune parameters return to baseline levels.

The study categorizes antibiotics based on spectrum and class, but there is inherent variability in how antibiotics are prescribed and used. Differences in dosage and duration of antibiotic treatment among participants can introduce variability in the results. Shorter or lower-dose treatments might have different impacts compared to longer or higher-dose regimens. The use of other medications alongside antibiotics, such as probiotics or other supplements, was not controlled for in the study. These additional treatments could influence the gut microbiome and immune responses, confounding the results.

The study relies on parental reporting for certain aspects of antibiotic use and health status between follow-up visits. Parents may not accurately remember or report all instances of antibiotic use

or health issues, leading to recall bias. This inaccuracy can affect the reliability of the data collected on antibiotic exposure and subsequent health outcomes. While parents are asked to maintain a diary of antibiotic use and health issues, adherence to this practice can vary, potentially resulting in incomplete or inconsistent data.

Despite efforts to control for confounding factors, some variables might still influence the results. Children's environments, diets, and lifestyles can significantly impact their microbiomes and immune systems. Variations in these factors among participants can confound the study's findings. Genetic differences among participants may affect their susceptibility to immune changes and microbiome disruptions caused by antibiotics. The study does not fully account for genetic variability.

Microbiome analysis through next-generation sequencing provides valuable data, but it has limitations. While sequencing can identify microbial diversity and composition, it might not provide detailed functional insights into how these changes impact immune responses. Functional studies are needed to complement microbial composition data. Periodic stool sample collection might not capture transient changes in the microbiome. More frequent sampling could provide a more detailed understanding of microbiome dynamics.

Comparison of Research Results with Previous Research

Many of the findings from this study are consistent with previous research, reinforcing the broader understanding of the relationship between antibiotic use and immune function in children. The study found significant reductions in gut microbiota diversity following antibiotic treatment, with younger children showing greater disruptions. Numerous studies have documented the impact of antibiotics on gut microbiota, highlighting decreased microbial diversity and altered community composition as common outcomes. Research by Jernberg et al. (2007) and Dethlefsen et al. (2008) also observed prolonged microbiota disruption following antibiotic treatment, particularly in young children whose microbiomes are still developing.

The study observed reductions in T cells, B cells, and immunoglobulin levels immediately following antibiotic use. Similar immune alterations have been reported in other studies. For instance, Penders et al. (2006) found that antibiotic use in infants was associated with altered immune cell populations and increased susceptibility to infections. Another study by Korpela et al. (2016) showed that antibiotic-induced microbiota changes correlated with immune dysfunction in children.

The study noted a higher incidence of respiratory and gastrointestinal infections in children with frequent antibiotic exposure. This finding aligns with earlier research indicating that antibiotic use, particularly broad-spectrum antibiotics, increases the risk of subsequent infections. Studies by Marra et al. (2006) and Kronman et al. (2012) reported similar patterns of increased infection rates following antibiotic treatment in pediatric populations.

The research found a higher prevalence of allergic diseases and autoimmune conditions in children exposed to antibiotics early in life. There is a substantial body of literature supporting this association. Research by McKeever et al. (2002) and Boursi et al. (2015) found correlations between early antibiotic use and the development of asthma, eczema, and autoimmune diseases like type 1 diabetes. These studies suggest that antibiotic-induced microbiota alterations may interfere with immune tolerance, leading to increased risk of allergies and autoimmune conditions.

While many findings are consistent with previous research, this study also provides novel insights and highlights areas where results diverge from existing literature. The study observed more pronounced immune disruptions in younger children (1–2 years) and slight gender-based differences, with boys showing higher susceptibility to immune changes. Although some studies have examined age-related differences, few have provided detailed analysis across specific age groups within early childhood. The gender differences observed are relatively novel, as most previous research has not extensively explored this aspect. This study's findings suggest that age and gender may play a more significant role in moderating the effects of antibiotics than previously understood.

The study highlighted sustained immune and microbiota changes even six months post-antibiotic treatment. While long-term effects have been noted in earlier studies, this research provides more detailed longitudinal data, showing the persistence of these changes over a significant period.

This adds to the growing evidence that the impact of antibiotics can be long-lasting, particularly in young children with developing immune systems.

The study differentiated the effects of broad-spectrum and narrow-spectrum antibiotics, finding more severe disruptions associated with broad-spectrum use. While the adverse effects of broad-spectrum antibiotics are well-documented, this study's comparative approach provides clearer evidence on the differential impacts of specific antibiotic classes. It underscores the importance of antibiotic selection in clinical practice to minimize adverse outcomes.

4. CONCLUSION

The study revealed that antibiotic use in young children leads to substantial disruptions in gut microbiota, with younger children experiencing more pronounced and prolonged disturbances. These microbiota alterations were associated with significant decreases in critical immune cell populations and immunoglobulin levels, indicating a compromised immune function. The increased susceptibility to infections and higher rates of allergic and autoimmune conditions observed among children with frequent antibiotic exposure highlight the broader health risks associated with antibiotic use. The research identified age and gender differences in the impact of antibiotics, with younger children and boys showing greater vulnerability. Additionally, the type of antibiotic used played a crucial role, with broad-spectrum antibiotics causing more severe disruptions compared to narrow-spectrum ones. These findings emphasize the need for personalized and judicious antibiotic prescribing practices in pediatric care. The results of this study have several implications for clinical practice. Improved antibiotic stewardship is essential, with a focus on limiting unnecessary prescriptions and opting for narrow-spectrum antibiotics when possible. Tailored prescribing practices that consider the age and gender of the child can help mitigate adverse effects. Enhanced monitoring and follow-up practices, including regular check-ups and support for gut health, are critical for children who have been prescribed antibiotics. Educational efforts to inform parents and caregivers about the potential risks and benefits of antibiotic use are also crucial. By understanding the implications of antibiotic treatment, parents can make more informed decisions and support non-antibiotic treatments when appropriate. Updated clinical guidelines that incorporate these findings will help healthcare providers make more informed prescribing decisions and promote the long-term health and well-being of children. Larger, more diverse studies with extended follow-up periods are necessary to fully understand the long-term effects of antibiotics on children's immunity. Future research should also explore the mechanisms underlying the observed immune changes and investigate the impact of various environmental and genetic factors.

REFERENCES

Amabile-Cuevas, C. F., Cardenas-Garcia, M., & Ludgar, M. (1995). Antibiotic resistance. *American Scientist*, *83*(4), 320–329.

Bengmark, S. (2013). Gut microbiota, immune development and function. *Pharmacological Research*, *69*(1), 87–113.

Coates, A. R. M., Hu, Y., Holt, J., & Yeh, P. (2020). Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction. *Expert Review of Anti-Infective Therapy*, *18*(1), 5–15.

Craig, J. C., Simpson, J. M., Williams, G. J., Lowe, A., Reynolds, G. J., McTaggart, S. J., Hodson, E. M., Carapetis, J. R., Cranswick, N. E., & Smith, G. (2009). Antibiotic prophylaxis and recurrent urinary tract infection in children. *New England Journal of Medicine*, *361*(18), 1748–1759.

Dancer, S. J. (2004). How antibiotics can make us sick: the less obvious adverse effects of antimicrobial chemotherapy. *The Lancet Infectious Diseases*, *4*(10), 611–619.

Fierz, W. (2004). Challenge of personalized health care: to what extent is medicine already individualized and what are the future trends. *Med Sci Monit*, *10*(5), 123.

Fong, W., Li, Q., & Yu, J. (2020). Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. *Oncogene*, *39*(26), 4925–4943.

Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017). The immune contexture in cancer prognosis and treatment. *Nature Reviews Clinical Oncology*, *14*(12), 717–734.

Gerber, J. S., Ross, R. K., Bryan, M., Localio, A. R., Szymczak, J. E., Wasserman, R., Barkman, D., Odeniyi, F.,

Conaboy, K., & Bell, L. (2017). Association of broad-vs narrow-spectrum antibiotics with treatment failure, adverse events, and quality of life in children with acute respiratory tract infections. *Jama*, *318*(23), 2325–2336.

Hand, T. W., Vujkovic-Cvijin, I., Ridaura, V. K., & Belkaid, Y. (2016). Linking the microbiota, chronic disease, and the immune system. *Trends in Endocrinology & Metabolism*, *27*(12), 831–843.

Jernberg, C., Lofmark, S., Edlund, C., & Jansson, J. K. (2010). Long-term impacts of antibiotic exposure on the human intestinal microbiota. *Microbiology*, *156*(11), 3216–3223.

Khan, M. F., & Wang, H. (2020). Environmental exposures and autoimmune diseases: contribution of gut microbiome. *Frontiers in Immunology*, *10*, 3094.

Komolafe, O. O. (2003). Antibiotic resistance in bacteria-an emerging public health problem. *Malawi Medical Journal*, *15*(2), 63–67.

Lamont, R. F., Luef, B. M., & Jørgensen, J. S. (2020). Childhood inflammatory and metabolic disease following exposure to antibiotics in pregnancy, antenatally, intrapartum and neonatally. *F1000Research*, *9*.

Langdon, A., Crook, N., & Dantas, G. (2016). The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. *Genome Medicine*, *8*, 1–16.

Levy, S. B. (2013). *The antibiotic paradox: how miracle drugs are destroying the miracle*. Springer.

McKeever, T. M., Lewis, S. A., Smith, C., Collins, J., Heatlie, H., Frischer, M., & Hubbard, R. (2002). Early exposure to infections and antibiotics and the incidence of allergic disease: a birth cohort study with the West Midlands General Practice Research Database. *Journal of Allergy and Clinical Immunology*, *109*(1), 43–50.

Metzler, S., Frei, R., Schmaußer-Hechfellner, E., von Mutius, E., Pekkanen, J., Karvonen, A. M., Kirjavainen, P. V, Dalphin, J., Divaret-Chauveau, A., & Riedler, J. (2019). Association between antibiotic treatment during pregnancy and infancy and the development of allergic diseases. *Pediatric Allergy and Immunology*, *30*(4), 423–433.

Niers, L., Stasse-Wolthuis, M., Rombouts, F. M., & Rijkers, G. T. (2007). Nutritional support for the infant's immune system. *Nutrition Reviews*, *65*(8), 347–360.

Permission, P. (1995). Informed consent, parental permission, and assent in pediatric practice. *Pediatrics*, *95*(2).

Schmidt, M. A. (2009). *Beyond antibiotics: Strategies for living in a world of emerging infections and antibiotic-resistant bacteria*. North Atlantic Books.

Shao, X., Ding, X., Wang, B., Li, L., An, X., Yao, Q., Song, R., & Zhang, J. (2017). Antibiotic exposure in early life increases risk of childhood obesity: a systematic review and meta-analysis. *Frontiers in Endocrinology*, *8*, 170.

Shekhar, S., & Petersen, F. C. (2020). The dark side of antibiotics: adverse effects on the infant immune defense against infection. *Frontiers in Pediatrics*, *8*, 544460.

Stolfi, C., Maresca, C., Monteleone, G., & Laudisi, F. (2022). Implication of intestinal barrier dysfunction in gut dysbiosis and diseases. *Biomedicines*, *10*(2), 289.

Yassour, M., Vatanen, T., Siljander, H., Hämäläinen, A.-M., Härkönen, T., Ryhänen, S. J., Franzosa, E. A., Vlamakis, H., Huttenhower, C., & Gevers, D. (2016). Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. *Science Translational Medicine*, *8*(343), 343ra81-343ra81.

Zhao, Q., & Elson, C. O. (2018). Adaptive immune education by gut microbiota antigens. *Immunology*, *154*(1), 28–37.